.

ISSN 2063-5346
For urgent queries please contact : +918130348310

BIOANALYTICAL METHOD DEVELOPMENT AND THERAPEUTIC DRUG MONITORING OF CARBAMAZEPINE

Main Article Content

Prathyusha Thunla, Akiladevi.D
» doi: 10.31838/ecb/2023.12.si4.082

Abstract

Carbamazepine is a standard antiepileptic medication that has structural similarities with tricyclic antidepressants. Carbamazepine in plasma may be detected using a variety of techniques, including Therapeutic Drug monitoring (TDM). Carbamazepine TDM has been touted as beneficial in a number of trials, although definitive criteria for TDM have yet to be established. Method: To evaluate Carbamazepine concentrations in human plasma, a bioanalytical technique was devised and validated using liquid chromatography (LC). Mean blood levels of Carbamazepine were 4995.54ng/mL in men and 3485.92ng/mL in females, according to an analysis of plasma concentrations in 84 epileptic participants receiving 100 to 400 mg/dose. Results: Inter- and intra-day precision at 70 ng/ml, 550 ng/ml, and 950 ng/ml for Carbamazepine are 0.02-0.04, 0.03-0.08, respectively, whereas for Diclofenac these values are 0.01-0.03 and 0.02. All of these values were calculated in accordance with ICH criteria. The findings of TDM for Carbamazepine with Diclofenac as a co-medication were statistically significant, with the mean blood levels reaching steady state in 84 patients using the medicine for a prolonged period of time. Mean serum concentrations were 4995.54ng/ml in women and 3485.92ng/ml in males. The total dosage range of the study was around 100 - 400 milligrams. Conclusion: The proposed technique for determining Carbamazepine concentration was quick, precise, and accurate. Consequently, randomized, controlled trials (RCTs) in a wider population with a broad range of dose to correspond with the population's overall serum levels and several co-medications for dose modifications to achieve the maximal safe dosage in the individual are anticipated

Article Details